News

Klotho Neurosciences, Inc. has announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc., a pioneer in cellular reprogramming and induced…
Read More...

Pfizer has announced a historic agreement with the Trump Administration aimed at significantly reducing prescription drug prices for American patients while reinforcing the U.S.'s…
Read More...

AbbVie has broken ground on a $70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, a key hub for the company’s biologics research, development, and…
Read More...

BioLineRx Ltd. and Norwegian biotech Hemispherian AS have established a joint venture to develop GLIX1, a first-in-class oral small molecule designed to target DNA damage response in…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib), an oral treatment for adult patients with chronic spontaneous urticaria (CSU)…
Read More...

AbbVie has begun construction on a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois, marking a major step in expanding its U.S. manufacturing…
Read More...

Labcorp, a global leader in laboratory services, announced a collaboration with Roche to implement the FDA-cleared VENTANA DP 600 and DP 200 digital slide scanners. This investment will…
Read More...

BenchSci, a global leader in AI for preclinical research and drug discovery, announced a strategic partnership with Thermo Fisher Scientific, the world leader in scientific services and…
Read More...

AstraZeneca and Daiichi Sankyo announced positive interim results from the DESTINY-Breast05 Phase III trial, reinforcing Enhertu’s (trastuzumab deruxtecan) potential as a foundational…
Read More...

Genmab A/S and Merus N.V. announced a definitive agreement under which Genmab will acquire all outstanding shares of Merus for $97.00 per share in an all-cash transaction valued at…
Read More...

Eisai and Biogen announced that China’s National Medical Products Administration (NMPA) has approved a once-every-four-weeks intravenous (IV) maintenance dosing schedule for LEQEMBI…
Read More...

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved its biologic therapy TREMFYA® (guselkumab) for use in children aged six years and older…
Read More...

Dyne Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation to DYNE-251, a therapy in development for Duchenne muscular…
Read More...

Amgen announced a $650 million expansion of its biologics manufacturing facility in Juncos, Puerto Rico, aimed at increasing drug production and integrating advanced technologies. This…
Read More...

Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Evkeeza (evinacumab-dgnb) for treating children aged 1 to under 5 years with homozygous…
Read More...

Er-Kim, an international pharmaceutical company focused on commercializing novel therapies across the EMEA region, has entered into a distribution agreement with Sentynl Therapeutics,…
Read More...

Biostar Pharma, the U.S. subsidiary of Beijing Biostar Biopharmaceutical, announced that its core drug candidate, Utidelone, has been granted Orphan Drug Designation (ODD) by the U.S.…
Read More...

Eli Lilly and Company has officially opened its newest Lilly Gateway Labs (LGL) location in San Diego, California, marking an expansion of its shared innovation hubs that support…
Read More...

Synaffix B.V., a Lonza company focused on advancing clinical-stage antibody-drug conjugate (ADC) technologies, has entered into a licensing agreement with South Korea–based…
Read More...

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company based in Allschwil, Switzerland, announced that it has been awarded a contract by the U.S. Biomedical Advanced…
Read More...